How does extracorporeal membrane oxygenation (ECMO) assist patients with refractory hypoxemia or severe hypercapnia?

How ECMO Helps Patients with Respiratory Failure

ECMO provides life-saving gas exchange by draining blood from the venous system, passing it through a membrane oxygenator that adds oxygen and removes carbon dioxide, then returning it to circulation—essentially functioning as an artificial lung for patients whose own lungs cannot maintain adequate oxygenation or ventilation despite maximal conventional therapy. 1

Mechanism of Action

VV-ECMO (Venovenous ECMO)

VV-ECMO is the primary configuration for respiratory failure. Blood is drained from the venae cavae via femoral or internal jugular venous cannulas, pumped through a membrane oxygenator at high flow rates (up to 7 L/min), and returned to the venous system. This provides full or partial extracorporeal pulmonary support by:

• Oxygenating blood when native lungs cannot achieve adequate gas exchange
• Removing carbon dioxide when ventilation is insufficient
• Allowing ultra-lung-protective ventilation by taking over gas exchange responsibilities, which reduces ventilator-induced lung injury 2, 3

The effectiveness of oxygenation depends critically on the ratio of ECMO blood flow to cardiac output—higher ECMO flow relative to cardiac output improves oxygen delivery 3.

VA-ECMO (Venoarterial ECMO)

VA-ECMO drains blood from the venous system but returns it to the arterial system (femoral or subclavian artery, or directly into the aorta). This provides both cardiac and pulmonary support, pumping up to 7 L/min, and is used when both heart and lung failure coexist 1.

Clinical Indications Based on Current Guidelines

The 2024 American Thoracic Society guidelines suggest VV-ECMO for selected patients with severe ARDS (conditional recommendation, low certainty of evidence) 2.

Specific Selection Criteria for VV-ECMO:

Patients must meet ALL of the following:

• Severe refractory hypoxemia: PaO₂/FiO₂ ratio < 80 mm Hg, OR
• Severe hypercapnia with acidosis: pH < 7.25 with PaCO₂ > 60 mm Hg
• Despite optimal conventional management, including:
  • Lung-protective ventilation
  • Higher PEEP
  • Neuromuscular blockade
  • Prone positioning
• Early in disease course: < 7 days into ARDS
• Reversible etiology of respiratory failure
• Few futility risk factors 2

Critical Timing Consideration

All less invasive therapies must be exhausted BEFORE considering ECMO—this includes lung-protective ventilation, higher PEEP, neuromuscular blockade, and prone positioning, as these may prevent the need for escalation 2.

Physiologic Benefits

For Hypoxemia:

• Directly oxygenates blood independent of native lung function
• Permits reduction in FiO₂ and ventilator pressures, minimizing oxygen toxicity and barotrauma
• Optimizing the ECMO flow-to-cardiac output ratio is key to maximizing oxygen delivery 3

For Hypercapnia:

• Efficiently removes CO₂ through the membrane oxygenator
• CO₂ clearance can be adjusted by modifying sweep gas flow through the oxygenator
• In refractory cases, double-parallel oxygenators can be used to increase membrane surface area for enhanced CO₂ removal 4
• Low-flow extracorporeal CO₂ removal (ECCO₂R) at 200-1,500 ml/min can manage hypercapnia when full ECMO is not needed 1

Important Caveats and Limitations

Resource Intensity and Center Experience

ECMO should only be performed at high-volume, experienced centers—institutional case volume directly correlates with improved outcomes 2, 1. The therapy requires:

• Specialized staffing and equipment
• Significant institutional resources
• Dedicated ECMO programs, ideally organized regionally 2

Evidence Quality

The certainty of evidence supporting ECMO is low due to:

• Limitations in landmark trials (CESAR trial lacked standardized ventilator management in controls and predated routine prone positioning)
• Substantial variability in center experience and outcomes
• Questions about real-world generalizability beyond expert centers 2

Health Equity Concerns

Disparities exist in patient selection based on insurance status, income, and gender—access to ECMO centers is variable and may have serious equity implications 2.

Contraindications to Consider

Avoid ECMO in patients with:

• Irreversible lung disease without transplant candidacy
• Advanced disease course (> 7 days of mechanical ventilation)
• Multiple organ failure with poor prognosis
• Conditions where resource diversion would harm other patients 2

Practical Implementation

When a patient meets criteria at a non-ECMO center, transfer to an ECMO-capable center should be considered when feasible 2. The decision must weigh:

• Feasibility of safe transport
• Center volume and expertise
• Cost-effectiveness for the institution
• Potential resource diversion from other critical needs 2

For refractory hypoxemia despite ECMO, advanced techniques include adding a second oxygenator in parallel using the same pump (sometimes requiring a second drainage cannula) to increase gas exchange capacity 5.